BioSpace News Archive

Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced that the U.S. Food and Drug Administration has approved Katerzia Oral Suspension, 1 mg/mL, the first and only FDA-approved amlodipine oral suspension.

DiscGenics, Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the first Utahns have been treated in its nationwide clinical study of IDCT, a locally developed injectable disc cell therapy for degenerative disc disease (DDD).

The American Heart Association today announced Opella Ernest, M.D., has been appointed president of the American Heart Association’s Metro Chicago Board of Directors.

Soliton, Inc. (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the company has identified an additional site and supervising physician for its upcoming expanded pivotal Cellulite Tria

TARIS Bio™ today announced the dosing of the first patient in a Phase 1b clinical trial evaluating the investigational product TAR-200 in combination with Opdivo® (nivolumab), a programmed death-1 (PD-1) immune checkpoint inhibitor from Bristol-Myers Squibb.

Hill-Rom Holdings, Inc. (NYSE: HRC), which recently rebranded as Hillrom, announced today that it has entered into a definitive agreement to sell certain surgical consumable products and related assets to an affiliate of Audax Private Equity (“Audax”) for $170 million in cash.

Spectrum Therapeutics (“Spectrum”), the medical division of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (the “Company” or “Canopy Growth”) is pleased to announce a partnership with the Canadian Mental Health Association (“CMHA”).

This is the First-in-Human Implementation for Geneos Therapeutics’ Exquisitely Personalized Immunotherapies for Cancer (GT-EPIC) Platform Clinical collaboration with Washington University

Respicardia Also Initiates 500-Patient Prospective, Global, Single-Arm Longitudinal Study

Tiaki Therapeutics, a company developing novel treatments to target the neuroinflammation that drives cognitive decline in patients with dementia, announced that Suzanne L. Bruhn, PhD, has been appointed as chief executive officer and president and joins the Board of Directors.